Catalent (NYSE:CTLT – Get Rating) had its target price lowered by Barclays from $62.00 to $58.00 in a report released on Tuesday, The Fly reports. The brokerage currently has an "overweight" rating on the stock. Barclays's price target would suggest a potential upside of 15.63% from the company's previous close.
Other research analysts have also issued reports about the stock. Argus lowered shares of Catalent from a "buy" rating to a "hold" rating in a research note on Monday, November 7th. Robert W. Baird decreased their price objective on shares of Catalent from $123.00 to $75.00 in a report on Wednesday, November 2nd. TheStreet downgraded shares of Catalent from a "b-" rating to a "c+" rating in a report on Friday, October 28th. Morgan Stanley decreased their price objective on shares of Catalent from $120.00 to $81.00 and set an "overweight" rating on the stock in a report on Thursday, November 3rd. Finally, KeyCorp decreased their price objective on shares of Catalent from $125.00 to $85.00 and set an "overweight" rating on the stock in a report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $92.40.
Get
Catalent alerts:
Catalent Trading Up 1.2 %
Shares of Catalent stock opened at $50.16 on Tuesday. Catalent has a 52-week low of $40.69 and a 52-week high of $115.33. The company has a quick ratio of 2.08, a current ratio of 2.86 and a debt-to-equity ratio of 0.87. The company's 50-day simple moving average is $46.33 and its 200-day simple moving average is $71.89. The firm has a market cap of $9.03 billion, a price-to-earnings ratio of 21.44, a price-to-earnings-growth ratio of 3.63 and a beta of 1.24.
Catalent (NYSE:CTLT – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.49 by ($0.24). Catalent had a return on equity of 12.55% and a net
margin of 8.83%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. As a group, equities research analysts anticipate that Catalent will post 2.93 earnings per share for the current year.
Insider Buying and Selling at Catalent
In related news, insider Manja Boerman sold 780 shares of the company's stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $51.70, for a total transaction of $40,326.00. Following the transaction, the insider now owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Manja Boerman sold 780 shares of the company's stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $51.70, for a total transaction of $40,326.00. Following the transaction, the insider now owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Grippo sold 2,451 shares of the company's stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $65.83, for a total transaction of $161,349.33. Following the transaction, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The disclosure for this sale can be found here. Insiders have sold 3,874 shares of company stock valued at $233,414 over the last quarter. Corporate insiders own 0.58% of the company's stock.
Hedge Funds Weigh In On Catalent
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bellevue Group AG acquired a new position in Catalent during the third quarter worth approximately $34,000. CX Institutional acquired a new position in Catalent during the second quarter worth approximately $37,000. Clear Street Markets LLC increased its position in Catalent by 408.1% during the second quarter. Clear Street Markets LLC now owns 376 shares of the company's stock worth $40,000 after purchasing an additional 302 shares during the last quarter. Motco acquired a new position in Catalent during the third quarter worth approximately $41,000. Finally, Alta Advisers Ltd acquired a new position in Catalent during the third quarter worth approximately $43,000. Institutional investors and hedge funds own 99.38% of the company's stock.
About Catalent
(Get Rating)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
